Mutations in the BRCA1 and BRCA2 genes confer a high lifetime risk of breast and ovarian cancer. The risk varies from individual to individual, and it appears that the risk has increased in recent generations. These observations imply that non-genetic factors may modify the inherited risk. To date, the factors that appear most strongly to modify the risk include reproductive histories and exogenous hormones. Oral contraceptives are associated with a profound reduction in the risk of ovarian cancer, and with little or no increase in the risk of breast cancer. Other modifying factors include age of menarche, parity, breastfeeding and oophorectomy. The effect of parity is different in BRCA1 and BRCA2 carriers. Multiparity appears to be protective in BRCA1 carriers, but is associated with an increase in risk in BRCA2 carriers. Oophorectomy has been associated with reductions in both the risk of breast and ovarian cancer. Knowledge of these risk factors will be useful for managing risk and for developing prevention strategies.
Introduction
Genetic counseling for women who are identified to carry a BRCA mutation is now widespread throughout Europe and North America. Among the goals of the genetic counselor are to estimate risk and to suggest strategies so that women may reduce their risk for breast and ovarian cancer. Knowledge of the factors that are associated with a reduced (or increased) risk is helpful when discussing strategies for prevention. Large epidemiology studies of gene carriers have been conducted to identify potential modifiers of risk. Depending on her level of risk, a woman may opt for intensive screening or for prophylactic surgery.
Risk is commonly measured in terms of the lifetime probability of developing breast or ovarian cancer (penetrance), but may also be communicated in terms of the probability of developing cancer in a given year. Penetrance is usually defined in terms of a given age (e.g. up to age 70 years) and can be estimated in several ways. Ideally, a cohort of healthy carriers of the susceptibility gene in question is followed for a defined period of time and incident (new) cases of cancer are recorded. The cancer rate is then calculated from the number of new cases and the person-years of observation. Other methods are used which depend on the reporting of cancers by family members. The lifetime risk of breast cancer in women who carry a deleterious BRCA1 or BRCA2 mutation is estimated to be as high as 80% -or roughly 10 times greater than that of the general population -but several estimates are lower (Ford et al., 1998; Risch et al., 2001; Antoniou et al., 2003; King et al., 2003) . In a cohort of 76 BRCA1 mutation carriers from Rotterdam, eight invasive cancers were detected during 318 person-years of follow-up (Meijers-Heijboer et al., 2001) -an annual incidence of 2.5%. Assuming a constant incident rate over 30 years of risk, this translates to a penetrance of approximately 75% for the Dutch population.
A specific penetrance estimate represents a population average, but penetrance may vary among populations, within populations and among individuals. There are several potential sources of variation. Allelic variation is due to different mutations of a single gene -for example, the position of the BRCA mutation within the coding region of the gene may influence the risk of breast or ovarian cancer. BRCA2 mutations that occur in the terminal portion of exon 27, and which result in the production of a nearly full-length protein, are believed not to be deleterious (Mazoyer et al., 1996) . Among BRCA2 carriers, the risk of ovarian cancer is greatest for women with mutations contained within the ovarian cancer cluster region (defined by nucleotides 4075-6503). The risk of ovarian cancer is increased by 1.9 times for mutations within this region and the risk of breast cancer appears to be decreased (Thompson and Easton, 2001) . Among BRCA1 mutation carriers, the relative proportion of ovarian cancer compared with breast cancer seems to be greater for mutations within the 5 0 two-thirds of the gene (Gayther et al., 1995) . Allelic variation can explain differences in penetrance among families and among countries. For example, the BRCA2 mutation commonly found in Israel is a 1 bp deletion in exon 11 (6174 del T) (Levy-Lahad et al., 1997) and the common BRCA2 mutation in Iceland is a 5 bp deletion in exon 9 (999 del 5) (Thorlacius et al., 1997) . In both countries, a single mutation accounts for the majority of cancer cases attributable to BRCA2, and therefore penetrance estimates derived from studies in these countries are mutation-specific (and not generalizable to other countries). In contrast, for the USA or the United Kingdom, the penetrance estimate will be based on a wide range of deleterious mutations.
Modifiers of penetrance
Another potential source of variation is that of modifying genes. The penetrance of a major gene might be conditional in the presence of one or more specific alleles of a genetic modifier. There could be one or more risk alleles (and one or more protective alleles) of the modifier. In the case of hereditary breast and ovarian cancer, several of the candidate modifier genes that have been studied are related to the metabolism of sex hormones and to DNA repair. There is some published data supporting the role of several of these genes (including androgen receptor, AIB1, HRAS and progesterone receptor) as potential modifiers of risk in BRCA1 or BRCA2 mutation carriers (Phelan et al., 1996; Rebbeck et al., , 2001 Runnebaum et al., 2001) . However, the results of different studies are inconsistent -for none of these is the evidence sufficiently strong to be used to guide clinical practice.
Modifiers of penetrance: hormonal factors
Environmental and lifestyle factors might also modify the risk of breast and ovarian cancer among carriers of BRCA mutations. Based on the inspection of multiplegeneration families, it has been proposed that the risk of breast cancer has increased among BRCA1 mutation carriers, that is, the penetrance of the gene for women born in recent generations is greater than that for those born earlier (Narod et al., 1993; Antoniou et al., 2003; King et al., 2003; Tryggvadottir et al., 2006) . This trend suggests that environmental factors (of increasing prevalence) could modify the risk. Some possible risk factors are discussed below. (Note that a cohort effect is different from the phenomenon of genetic anticipation. In genetic anticipation, the penetrance of a gene increases with subsequent generations after the de novo occurrence of the mutation. Anticipation is often owing to unstable (dynamic) mutations, but for some conditions, such as hereditary retinoblastoma, the basis for anticipation is unexplained. However, in contrast to a cohort effect, there is no general relationship between penetrance and calendar year with genetic anticipation. Furthermore, the common BRCA mutations are believed to have occurred at least 50 or more generations ago -and it is improbable that the penetrance could increase significantly over just a few generations owing to mutation instability.)
Age of menarche
The age at which a woman experiences her first menstrual period influences her subsequent risk of breast cancer. It is not clear if this implies that neoplastic events take place in women as early as age of 10 years, or if the age of menarche is an indicator of later hormonal events, such as the regularity of established menses or circulating hormone levels. Early menarche is associated with an increased risk of breast cancer in BRCA1 carriers . Compared to women who experienced menarche at or before the age of 11 years, women with late menarche (at or after the age of 14 years) experienced a 54% reduction in breast cancer risk (odds ratio (OR) ¼ 0.46, 95% confidence interval (CI): 0.30-0.69).
Spontaneous and therapeutic abortion
An interruption in pregnancy might be expected to be carcinogenic because the early changes of pregnancy result in increased mitoses, but are not accompanied by the later differentiation of the epithelial cells. In one study, there was no effect of spontaneous abortion on the subsequent risk of breast cancer in BRCA1 or BRCA2 carriers (Friedman et al., 2006) . However, a modest protective effect of therapeutic abortion was found in BRCA2 carriers; compared to women who never had a therapeutic abortion, BRCA2 carriers with two or more therapeutic abortions experienced a 64% reduction in breast cancer risk (P ¼ 0.02). No similar effect was observed for BRCA1 carriers.
Pregnancy
In the general population, pregnancy offers protection against breast cancer after the age of 40 years, but appears to increase the risk for very early-onset breast cancer. This is consistent with the hypothesis that the ovarian hormones produced during pregnancy are mitogenic and accelerate the growth of existing tumors. During pregnancy, breast differentiation occurs and thereafter the population of susceptible cells is reduced (Russo et al., 1992) . This might explain why pregnancy prevents breast cancers at a later age. The effect of pregnancy on hereditary breast cancer risk appears to differ for BRCA1 and BRCA2 carriers. In a large matched case-control study, Cullinane et al. (2005) reported that the risk of breast cancer did not decrease with pregnancy in BRCA1 carriers until four births were reached, after which there was only a modest protective effect. However, among BRCA2 carriers, there was a statistically significant increase in breast cancer risk with each additional pregnancy (OR ¼ 1.17, 95% CI: 1.01-1.36; P ¼ 0.03). Furthermore, an early first birth does not appear to be protective for breast cancer risk among BRCA1 carriers . This is consistent with the theory of Russo et al. (2001) that, in the absence of intact BRCA1, pregnancy fails to induce the expected degree of lobular differentiation.
Breastfeeding
A case-control study of breast-feeding and breast cancer in BRCA mutation carriers reported a significant protective effect in women with BRCA1 mutations, but not with BRCA2 mutations (Jernstrom et al., 2004) . BRCA1 mutation carriers who breast-fed for more than 1 year were 40% less likely to have breast cancer than those who breast-fed for a shorter period (P ¼ 0.01).
Oophorectomy
Several studies have reported that the incidence of breast cancer declines in women with BRCA1 or BRCA2 mutations following an oopohorectomy Kauff et al., 2002; Eisen et al., 2005) . In the largest of these, Eisen et al. (2005) performed a casecontrol study on 1439 BRCA mutation carriers with breast cancer, and 1866 matched controls without breast cancer. Among BRCA1 mutation carriers, the risk of breast cancer among women who had an oophorectomy was decreased by 56% (OR ¼ 0.44, 95% CI: 0.29-0.66) (Eisen et al., 2005) . A protective effect was observed among both BRCA1 and BRCA2 mutation carriers for 15 years following oophorectomy (OR ¼ 0.39, 95% CI: 0.26-0.57). Together, these studies suggest that oophorectomy might be a strategy to decrease the risk of breast cancer among BRCA1 and BRCA2 mutation carriers.
Oral contraceptives
It is important to establish whether or not oral contraceptives are hazardous to the breast, because their use has been proposed as a preventive measure against ovarian cancer (in a recent study of 232 ovarian cancer cases and 232 controls, oral contraceptive use was associated with a 56% reduction in the risk of ovarian cancer (OR ¼ 0.44; P ¼ 0.002) Narod et al., 1998 ). There appears to be a small increase in breast cancer risk associated with pill use among BRCA1 mutation carriers (Narod et al., 2002) . Even use of oral contraceptives was associated with a modestly increased risk of breast cancer (OR ¼ 1.20, 95% CI: 1.02-1.40). Compared with BRCA1 mutation carriers who never used oral contraceptives, those who used oral contraceptives for at least 5 years had an increased risk of breast cancer (OR ¼ 1.33, 95% CI: 1.11-1.60), as did those who used oral contraceptives before the age of 30 years (OR ¼ 1.29, 95% CI: 1.09-1.52), those who were diagnosed with breast cancer before the age of 40 years (OR ¼ 1.38; 95% CI: 1.11-1.72), and those who first used oral contraceptives before 1975 (OR ¼ 1.42; 95% CI: 1.17-1.75).
Tamoxifen and raloxifene
Tamoxifen is an anti-estrogenic drug, which is routinely used in the treatment of estrogen-receptor-positive breast cancers. Tamoxifen has also been demonstrated to be of value in reducing the risk of primary invasive and pre-malignant breast cancer in high-risk women in North America (Fisher et al., 1998) , and of contralateral breast cancer in unselected women (Early Breast Cancer Trialists' Collaborative Group, 1998) . The large National Surgical Adjuvant Breast and Bowel Project (NSABP) breast cancer prevention trial reported a highly significant reduction in the incidence of invasive breast cancer among women randomized to tamoxifen, versus placebo (Fisher et al., 1998) . In an subset analysis of the NSABP database, genetic mutation status was determined by DNA sequencing on 288 women with incident breast cancer (King et al., 2001) . Nineteen carriers were identified; five of eight women with BRCA1 mutations had taken tamoxifen, versus three of 11 women with BRCA2 mutations. These data suggest that tamoxifen may be effective in the primary prevention of BRCA2 mutation-associated breast cancer, but not of BRCA1 mutation-associated breast cancer. However, the data set was very small and neither result was statistically significant. The power to detect a moderate protective effect was low in this study.
The effect of tamoxifen on contralateral breast cancer has been studied in a case-control study of BRCA1 and BRCA2 mutation carriers (Gronwald et al., 2006) . The multivariate OR for contralateral breast cancer associated with tamoxifen use was 0.50 for carriers of BRCA1 mutations (95% CI: 0.30-0.85) and was 0.42 for carriers of BRCA2 mutations (95% CI: 0.17-1.02), implying a risk reduction of 50% or more. Most women were given tamoxifen for estrogen-receptor-positive cancers, and there is concern that the drug may only prevent estrogen-receptor-positive contralateral cancers. However, Weitzel et al. (2005) showed that, even after an estrogen-receptor-positive cancer, the majority of contralateral breast cancers in BRCA carriers are in fact, estrogen-receptor-negative. If the results of the study of contralateral breast cancer can be extrapolated to the prevention of primary breast cancers, then tamoxifen chemoprophylaxis in BRCA mutation carriers is likely to be protective.
Hormone replacement therapy
There is little data available so far that supports the hypothesis that hormone replacement therapy (HRT) increases the risk of breast cancer in women at high genetic risk. In the only study published to date, Rebbeck et al. (2005) reported that the protective effect offered by oophorectomy was not attenuated by the prescription of HRT. Compared to women who did not have an oophorectomy, the combination of HRT and oophorectomy was associated with a significant reduction in breast cancer risk (hazard ratio ¼ 0.37, 95% CI: 0.14-0.96).
Antioxidants
The potential for the antioxidants to be used as chemoprevention in BRCA carriers has been discussed elsewhere (Kotsopoulos and Narod, 2005) . Coffee has antioxidant properties, and drinking six or more cups of caffeinated coffee a day has been reported to be associated with a significantly reduced risk of breast cancer in BRCA1 carriers (Nkondjock et al., 2006) . Other effects of coffee are to modify the ratio of circulating estrogen metabolites in a favorable direction (Jernstrom et al., 2003) . Selenium also has antioxidant properties. Oral selenium supplementation has been shown to reduce the number of bleomycin-induced chromosome breaks in BRCA1 mutation carriers (Kowalska et al., 2005) .
Conclusions
We are beginning to see the emergence of different risk factor profiles for BRCA1 and BRCA2 mutation carriers. The proposed modifiers of breast cancer risk in BRCA1 carriers relate to estrogen exposure and deprivation. The risk of breast cancer declines after menopause; the cancers are largely limited to the breast and ovary, and breast cancer is preventable by tamoxifen and by oophorectomy. The evidence for the importance of hormones in BRCA2-related carcinogenesis is much less compelling. The range of cancers seen among BRCA2 mutation carriers is wide and includes types that are classically associated with exogenous carcinogens, including melanoma and pancreatic cancer (The Breast Cancer Linkage Consortium, 1999) . Breast cancer affects males as well as females, and there is no apparent postmenopausal decline in breast cancer risk. In one recent study, the risks of all cancers combined were similar for male and female relatives of BRCA2 mutation carriers (Risch et al., 2001) . To date, most of the preventive strategies have been based on estrogen blockade, but there is emerging evidence that antioxidants may be a complementary route of prevention. It is hoped that chemoprevention regimens, which incorporate anti-estrogens and antioxidants, will lead to a dramatic reduction in breast cancer risk, but it will be a challenge to identify the optimal agents and the proper indications.
